All Categories
Artera Expands Its Validated Multimodal AI Platform to Metastatic...
First digital pathology-based test to provide individual risk estimates to help inform treatment planning in mHSPC SAN FRANCI [...]
FDA approves first AI test to guide breast cancer...
As of 2022, there were about 2.3 millionTrusted Source women around the world newly diagnosed with breast cancer, and about 6 [...]
ArteraAI Offers a New Approach to Breast Cancer Treatment...
Matthew Kurian, MD, examines ArteraAI Breast, a newly FDA-cleared multimodal platform that combines pathology imaging and cli [...]
Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announ [...]
For Women Over 50, AI Could Change Breast Cancer...
For women over 50, a breast cancer diagnosis often comes with a difficult and deeply personal question: Do you really need ch [...]
He Was Told He Needed Surgery for Cancer: A...
When Howard Wolinsky went in for a routine checkup in his mid-50s. He thought he was doing everything right. “I was just bein [...]
CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized...
Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHH [...]
ASCO to shine light on multimodal AI models: Plus,...
Dr. Lu will highlight recent work using specimens from the NRG B-20 trial, in which investigators applied multimodal AI appro [...]